Literature DB >> 34970431

Non-selective beta-blocker use in cirrhosis: the additional benefit in preventing secondary infections.

Rooshi Nathwani1,2, David Kockerling1,2, Benjamin H Mullish1,2, Alexander Cole1,2, Maud Lemoine1,2, Charalambos Gustav Antoniades1,2, Mark R Thursz1,2, Ameet Dhar1,2.   

Abstract

Entities:  

Keywords:  bacterial infection; cirrhosis; portal hypertension

Year:  2021        PMID： 34970431      PMCID： PMC8666853          DOI： 10.1136/flgastro-2021-101818

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN： 2041-4137


× No keyword cloud information.
  7 in total

1.  Second infections independently increase mortality in hospitalized patients with cirrhosis: the North American consortium for the study of end-stage liver disease (NACSELD) experience.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; K Rajender Reddy; Florence Wong; Jody C Olson; Ram M Subramanian; Geri Brown; Nicole A Noble; Leroy R Thacker; Patrick S Kamath
Journal:  Hepatology       Date:  2012-12       Impact factor: 17.425

2.  Survival in infection-related acute-on-chronic liver failure is defined by extrahepatic organ failures.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; K Rajender Reddy; Florence Wong; Scott W Biggins; Heather Patton; Michael B Fallon; Guadalupe Garcia-Tsao; Benedict Maliakkal; Raza Malik; Ram M Subramanian; Leroy R Thacker; Patrick S Kamath
Journal:  Hepatology       Date:  2014-05-29       Impact factor: 17.425

Review 3.  Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance.

Authors:  Agustín Albillos; Margaret Lario; Melchor Álvarez-Mon
Journal:  J Hepatol       Date:  2014-08-15       Impact factor: 25.083

4.  Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis.

Authors:  Vasiliki Arvaniti; Gennaro D'Amico; Giuseppe Fede; Pinelopi Manousou; Emmanuel Tsochatzis; Maria Pleguezuelo; Andrew Kenneth Burroughs
Journal:  Gastroenterology       Date:  2010-06-14       Impact factor: 22.682

5.  Cirrhosis as a risk factor for sepsis and death: analysis of the National Hospital Discharge Survey.

Authors:  Marilyn G Foreman; David M Mannino; Marc Moss
Journal:  Chest       Date:  2003-09       Impact factor: 9.410

6.  Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013.

Authors:  Rajiv Jalan; Javier Fernandez; Reiner Wiest; Bernd Schnabl; Richard Moreau; Paolo Angeli; Vanessa Stadlbauer; Thierry Gustot; Mauro Bernardi; Rafael Canton; Agustin Albillos; Frank Lammert; Alexander Wilmer; Rajeshwar Mookerjee; Jordi Vila; Rita Garcia-Martinez; Julia Wendon; José Such; Juan Cordoba; Arun Sanyal; Guadalupe Garcia-Tsao; Vicente Arroyo; Andrew Burroughs; Pere Ginès
Journal:  J Hepatol       Date:  2014-02-12       Impact factor: 25.083

7.  Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes.

Authors:  Mathias Jachs; Lukas Hartl; Dunja Schaufler; Christopher Desbalmes; Benedikt Simbrunner; Ernst Eigenbauer; David Josef Maria Bauer; Rafael Paternostro; Philipp Schwabl; Bernhard Scheiner; Theresa Bucsics; Albert Friedrich Stättermayer; Matthias Pinter; Michael Trauner; Mattias Mandorfer; Thomas Reiberger
Journal:  Gut       Date:  2020-11-16       Impact factor: 23.059
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.